Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 67-year-old woman with pneumonia and diabetes mellitus was admitted with the complaints of abdominal and back pain. Sputum culture was positive for Klebsiella pneumoniae. Computed tomographic scanning (CT) of the abdomen and spinal radiograph of the lumber column revealed a paraventebral space-occupying lesion, abdominal aortic aneurysm and destructive change of L3 and L4. Pseudoaneurysm of the abdominal aorta associated with infectious spondylitis with paravertebral abscess was suspected and confirmed by aortography. Klebsiella pneumoniae was cultured from the abscess. The patient's condition improved rapidly after drainage of the abscess and administration of LMOX and gentamicin. Infectious pseudoaneurysm of the abdominal aorta associated with infectious spondylitis has rarely been reported. These two in combination due to Klebsiella pneumoniae has not been reported to our knowledge. The pathologic changes were found easily by CT scan. When infectious aneurysm or infectious spondylitis is diagnosed alone, possible combination of these diseases should be kept in mind.
 ...
PMID:A case of infectious pseudoaneurysm of the abdominal aorta associated with infectious spondylitis due to Klebsiella pneumoniae. 266 92

The in vitro antibacterial activity of cefminox (CMNX, MT-141) was nearly equal to that of CTX, LMOX, CMZ and CPZ against the 4 species of clinically isolated strains. CMNX was applied to a total of 17 patients including 11 cases of bronchitis, 4 cases of pneumonia and 2 cases of urinary tract infection. The results showed an efficacy rate of 94% (16/17). In the 4 patients from whom the isolation of pathogenic organisms was possible, the bacteriological response to CMNX was appreciable the efficacy rate being 80% (4/5). No side effect of the drug was observed.
 ...
PMID:[Clinical studies of cefminox in the pediatric field]. 383 63

Laboratory and clinical studies on ceftazidime ( CAZ ), a new cephem antibiotic, were carried out in the field of pediatrics. The results were as follows: Antibacterial activities of CAZ against clinically isolated strains of S. pneumoniae, H. influenzae, E. coli and P. aeruginosa were compared with those of cefotaxime (CTX), ceftizoxime (CZX), latamoxef ( LMOX ), cefoperazone (CPZ) and cefmetazole (CMZ), and also with cefsulodin (CFS) and gentamicin (GM) against P. aeruginosa. Against S. pneumoniae and H. influenzae, CAZ was almost as active as CTX, CZX and CPZ. Against E. coli, it was almost as active as CTX, CZX and LMOX . Against P. aeruginosa, it was almost as active as CFS and GM. Serum concentrations and urinary excretion rates after intravenous bolus injection of CAZ at doses of 20 mg/kg and 10 mg/kg for 5 minutes in each 2 cases (4 cases in total) were determined. The mean serum concentrations of CAZ were 78.9 and 52.0 micrograms/ml at 15 minutes, 38.5 and 27.4 micrograms/ml at 1 hour, and 6.5 and 4.8 micrograms/ml at 4 hours, with serum half-lives (T 1/2) of 1.39 and 1.80 hours respectively. Mean cumulative urinary excretion rate within 6 hours after administration was 84.6%. In a patient with chronic renal failure, serum half-life was 3.22 hours and urinary excretion rate within 6 hours was 22.8% (after intravenous bolus injection of CAZ at a dose of 10 mg/kg). CAZ was administered at a dose of 55.5 mg/kg by intravenous bolus injection to a child with purulent meningitis. The levels of CAZ in the cerebrospinal fluid (CSF) at 1 hour after administration were 2.7-38.9 micrograms/ml with CSF/Serum ratios of 3.2-28.8%. Forty-two pediatric patients with various bacterial infections (pyelonephritis 14, tonsillitis 1, bronchopneumonia 3, pneumonia 17, purulent meningitis 1, bacteremia 2, SSSS 1, enterocolitis 3) were treated with CAZ at a daily dose of 49-222 mg/kg t.i.d. or q.i.d. (as a rule 60 mg/kg t.i.d.). The efficacy rate was 97.6% clinically and 97.8% bacteriologically. No adverse reactions were observed except 1 case with mild diarrhea. Abnormal laboratory findings were also only mild; eosinophilia in 1, slight elevation of GOT in 5 and that of GOT & GPT in 3 cases. These results indicate the usefulness of CAZ in the treatment of bacterial infections in children.
 ...
PMID:[Laboratory and clinical studies on ceftazidime in the field of pediatrics]. 637 56

The current state of causative bacteria in infectious diseases and the trends in resistance to antimicrobial agents were mentioned. The commonest micro-organisms isolated from the blood and intravascular catheter tips were CNS, S. aureus and C. albicans. Significant urine culture isolates were E. coli and other enterobacteriaceae in uncomplicated UTI, and Enterococcus spp. and Pseudomonas spp. in complicated UTI with a urinary catheter. In respiratory tract infections (RTIs), H. influenzae, S. pneumoniae, B. catarrhalis, S. aureus and P. aeruginosa, were common causative organisms. Community-acquired pneumonia was mainly caused by H. influenzae, S. pneumoniae and B. catarrhalis. In common with hospital-acquired pneumonia, P. aeruginosa, S. aureus and enterobacteriaceae were the frequent microorganisms isolated. In anaerobic infections, the most common micro-organisms were B. fragilis and other B. fragilis group isolated from intra-abdominal focus of post operative patients. The trends in the antimicrobial susceptibility of isolates of common bacteria over a period of 5 years (1988-1992) have been monitored. The proportion of isolates of S. aureus resistant to CEZ, CMZ, FMOX, IPM or MINO has increased. There was no trend towards increased resistance among isolates of P. aeruginosa except for CBPC. The incidence of resistance to PCG, ABPC, EM and LMOX increased in isolates of S. pneumoniae and that of resistance to PIPC, CMZ, LMOX and IPM increased in those of B. fragilis group.
 ...
PMID:[Current state of causative bacteria in infections diseases and trends in resistance to antimicrobial agents]. 812 76